A randomized, placebo-controlled trial of the dopamine-b-hydroxylase (DBH) inhibitor, nepicastat, for the treatment of PTSD in OIF/OEF veterans.

Trial Profile

A randomized, placebo-controlled trial of the dopamine-b-hydroxylase (DBH) inhibitor, nepicastat, for the treatment of PTSD in OIF/OEF veterans.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs Nepicastat (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 May 2013 Biotie is evaluating data from this study in further detail and will then decide on next steps with nepicastat in PTSD, according to a company media release.
    • 27 Dec 2012 Results have been reported in a Biotie Therapeutics media release.
    • 27 Dec 2012 Status changed from recruiting to completed based on information reported in a BioTie Therapies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top